American Century Companies Inc. Has $3.21 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

American Century Companies Inc. boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,808 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,097 shares during the period. American Century Companies Inc. owned about 0.31% of Collegium Pharmaceutical worth $3,214,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of COLL. ProShare Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 3.3% during the 1st quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 281 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in Collegium Pharmaceutical by 1.9% during the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock worth $531,000 after acquiring an additional 300 shares in the last quarter. Texas Permanent School Fund Corp raised its stake in Collegium Pharmaceutical by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after acquiring an additional 369 shares in the last quarter. SummerHaven Investment Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 1.3% in the second quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company’s stock worth $1,120,000 after acquiring an additional 452 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 535 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Truist Financial raised their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Finally, HC Wainwright lifted their price target on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $38.47 on Friday. The business has a 50-day moving average of $36.57 and a 200-day moving average of $35.50. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 16.03 and a beta of 0.94. Collegium Pharmaceutical, Inc. has a 1 year low of $20.95 and a 1 year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. During the same quarter last year, the business earned $1.13 EPS. The company’s revenue was up 7.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.